Crohn's disease (CD) is an idiopathic inflammatory disorder characterized by transmural inflammation of the gastrointestinal tract with a relapsing and remitting course requiring frequent disease evaluations. Clinical indices have been developed to evaluate and quantify the severity of disease. The most commonly utilised of such indices are the Crohn's Disease Activity Index and Harvey Bradshaw Index, which grade the severity of the disease from asymptomatic remission to severe disease.
Colonoscopy remains the preferred method of mucosal evaluation. However, major limitations of colonoscopy include its inability to stage disease severity in the small bowel, and to evaluate extraluminal complications. Due to these shortcomings, gastroenterologists require the input of noninvasive cross-sectional imaging techniques in order to assess disease severity.
Computed tomography enterography (CTE) is widely used in the assessment of severity and complications of CD. Unfortunately, patients are often subjected to frequent examinations increasing their exposure to ionizing radiation. Given the chronicity of the disease and the young age of most patients at onset, a technique not utilising harmful radiation is preferred. As an alternative, magnetic resonance enterography (MRE) is an effective method to demonstrate disease activity and CD-associated complications without the use of ionizing radiation [1e3] . MRE utilises oral agents for bowel distension, and intravenous (IV) contrast for wall enhancement.
Numerous studies have demonstrated MRE to be of comparable or higher sensitivity and specificity in the detection of signs of CD, such as small bowel pathologies, including mucosal lesions, bleeding, as well as fistulas, abscesses, and stricturing disease [4e9] .
With the increasing use of MR as an imaging technique in CD, there have been attempts to develop MR-based severity indices. Such index of activity, Crohn's Disease Endoscopic Index of Activity (CDEIS) has been developed and widely used based on endoscopic findings. The CDEIS is calculated in 5 segments (terminal ileum, right colon, transverse colon, left colon, and rectum) and takes into account the involved area, the ulcerated areas, and the presence of deep or superficial ulcers. This score is mainly used in clinical trials to assess endoscopic response [10] . Rimola et al [11e14] proposed and validated an MRI based grading scheme called Magnetic Resonance Index of Activity (MaRIA) to assess disease severity in the same anatomical location. The MaRIA grading scheme includes wall thickness, relative contrast enhancement, and the presence of oedema and ulcers as identified on MRI. They were able to demonstrate that the MaRIA score correlated very well with the CDEIS in terms of predicting mucosal healing (MaRIA <7) and ulcer healing (MaRIA <11), with a 90% sensitivity and 94% specificity [11e14] .
MRI is accurate in depicting inflammatory changes of the bowel (mucosal enhancement, submucosal oedema or enhancement, increased vascularity, and inflammatory changes of surrounding adipose tissue), but few studies [15] have tried to investigate the impact of MRE on patient management.
The purpose of the current study is to evaluate the impact of specific MRE signs on the management of CD.
Methods
We performed a retrospective cohort study by including all consecutive adult patients who had an MRE between June 2011 and December 2012 and that had a previously established diagnosis of CD based on endoscopy and histology. The patients had to be seen by their gastroenterologists after the MRE. Patients with indeterminate colitis or with a diagnosis of CD established by MRE only were excluded. This study was approved by the McGill University Hospital Centre Ethics Committee. Baseline patient characteristics for those included in the study are shown in Table 1 .
MRE Protocol
All MREs were performed using an MR machine by General Electric, 1.5-T SIGNA Excite model. The patients were asked to fast for at least 8 hours prior to the MRE. Patients were given 750 mL of a diluted lactulose solution to drink prior to the examination (250 mL of a 667 mg/mL solution of lactulose was diluted in 750 mL of water). Patients were first instructed to drink 500 mL of the lactulose solution, followed by 250 mL 20 minutes later. Provided that there were no contraindications, patients were given 40 mg of Hyoscine (Buscopan; Boehringer Ingelheim, Ingelheim am Rhein, Germany) through the IV route (2 mL of a 20 mg/mL Hyoscine solution) in 2 separate doses of 20 mg IV, one following the kinematic sequence and the other prior to the contrast sequences. Scanning started 45 minutes after the initial dose of oral contrast. The patients were supine for the examination. Respiratory triggered or expiration triggered MRI was performed, depending on the patient's abilities and understanding of the breathing instructions. An 8-channel body array coil pad set was used (one coil was used to cover the abdomen and the other was placed underneath the patient).
Sequences used as per protocol were as follows: a coronal T2 single-shot fast-spin echo (SSFSE) (breath hold or respiratory trigger), axial T2 SSFSE (upper) (breath hold or respiratory trigger), T2 SSFSE (lower) (breath hold or respiratory trigger), axial T2 SSFSE fatsat (upper) (breath hold or respiratory trigger), axial T2 SSFSE fatsat (lower) (breath hold or respiratory trigger), coronal T2 fast imaging employing steady-state acquisition (FIESTA) (breath hold), axial T2 FIESTA (upper) (breath hold), axial T2 FIESTA (lower) (breath hold), coronal liver acceleration volume acquisition (LAVA) (breath hold), axial delay (upper) (breath hold), axial delay (lower) (breath hold), and coronal Kinematic FIESTA (breath hold, 20 phases per slice to cover the entire abdomen, repetition time: min, echo time: min; full matrix: 256 Â 256, flip angle: 75, slice thickness/gap: 7 mm/0 mm). The dose of the IV contrast gadobutrol (Gadavist; Bayer HealthCare Pharmaceuticals Inc, Whippany, NJ) was determined by weight, raging from a minimum of 6 cc to a maximum of 16 cc. Delayed images were taken 25 seconds after injection.
Data Collection

Clinical and demographic data
Information pertaining to presence of perianal disease, disease location ( [16] were obtained. This classification system for inflammatory bowel disease is an integrated clinical (including clinical severity of the disease, as well as disease location), molecular, and serological classification, developed by a party of investigators and reported at the 2005 Montreal World Congress of Gastroenterology. Demographic data, including age, gender, smoking status, and duration of disease at the time of the MRE study were also collected. Further information pertaining to previous surgeries, medication use before and after MRE, and recent C-reactive protein (CRP) prior to MRE were also gathered retrospectively by chart reviews.
Prior imaging
A search was performed to establish whether our patients had had prior imaging performed within 3 months of the MRE study. In this search we included other MREs, CT scan of abdomen with or without contrast, CTE, ultrasound of the abdomen and pelvis, small bowel barium follow-through studies, and barium enemas.
MRE reports
MREs were reported by 4 abdominal radiologists with at least 5 years of experience in reading MREs. Original MRE reports from our tertiary care centres were reviewed retrospectively, and no rereading of MREs was performed. Because subsequent management by gastroenterologists had made use of the original MRE reports, we used these same reports for our statistical analysis.
Signs pertaining to disease activity were collected based on original MRE reports. These signs are listed in Table 2 . Small bowel motility was assessed subjectively by the radiologists on the coronal Kinematic FIESTA sequence as either normal or decreased. MREs that had none of these signs were considered, for the sake of the analysis, to be normal MREs. All other MREs were considered abnormal.
Gastroenterology follow-up and patient management
Decisions made by gastroenterologists after reviewing the original MRE reports were gathered, and management decisions were divided into the following 4 categories: no change, change in dose of medication, addition or substitution of medication (including steroids), and surgery and hospitalization.
Statistical analysis
Fisher's test was used to examine the significance of the association between each MRE finding and changes in patient management. Confidence limits were calculated for the odds ratios (ORs). The Wilcoxon rank sum test and the Student t test were used to examine the relationship of CRP levels and age to change in management, respectively. We then used a multivariate logistic regression model to calculate the predicted probability of change in management for given findings on MRE after correction for other potential contributors, such as CRP. The stepwise model selection method was used to identify the explanatory variables in the logistic regression. A significance level of 0.3 and 0.2 was set for variable entry and variable stay, respectively. Finally, using the assumption that different categories of change are levels of change falling on a spectrum, with no change being at one end of the spectrum and hospitalization and surgery on the opposite end, we performed an ordinal outcome analysis using the Wilcoxon rank sum test. For the sake of these analyses, each MRE was considered an independent event. P values <.05 were considered significant. All analyses were performed with SAS, version 9.2 (SAS Institute, Cary, NC).
Results
Over the study period, 66 MREs were performed on 62 patients, 41 women and 21 men with established CD. Table 1 highlights the different baseline characteristics of the patients included.
Prior Imaging
Six patients had a total of 6 ultrasounds and 2 abdominopelvic CT scans within the 3-month period prior to their MRE study. Of these studies, one ultrasound study was preceded by non-enhanced CT scan of the abdomen (see Table 2 ).
None of our patients had had CTE, small bowel barium follow-through, or barium enema studies performed within the 3-month period prior to their MRE study.
MRE Reports
Twenty-four different MRE findings were reported by radiologists with an average of 3.7 findings per MRE, ranging from 0-10 findings. The 5 most common findings included circumferential wall thickening, wall enhancement post gadolinium, reactive lymph nodes, luminal narrowing, and fat stranding ( Table 3 ). Of the 66 MREs performed, 8 (12.1%) were considered normal, and, of those, only 1 (12.5%) had a change in management. Fifty-eight (87.9%) MREs were considered abnormal, of which 37 (63.8%) cases had a change in management. Overall, having an abnormal MRE was strongly associated with a change in management (OR: 12.33; 95% confidence interval [CI]: 1.38-570.43; P ¼ .008).
After completion of the MREs, a change in management occurred in a total of 38 (57.6%) cases, with some post-MRE follow-up decisions fitting more than 1 category of change. Ten patients underwent a change in dose of medication, 25 had a change in medication or addition of steroids, and 7 underwent a surgical intervention. Of all 7 patients who had a surgical intervention, 1 required it for fistula repair and relief of small bowel adhesions, 1 for uncontrollable disease despite escalation in biologic therapy, 1 for fistula closure and ileocecal resection, 2 for fibrostenotic disease, 1 for ileocecal resection in the context of abscess, and 1 for drain placement in the context of abscess.
Association Between Specific MRE Findings and Change in Management
Patients who had a change in management were more likely to have findings of circumferential wall thickening on MRE (OR: 3.9; 95% CI: 1.24-12.47; P ¼ .01) as well as reactive lymph nodes, but the latter was only marginally significant (OR: 3.4; 95% CI: 0.94-13.49; P ¼ .06). Patients with a change in dose of medication were more likely to have tethering of adjacent mesentery (OR: 13.8; 95% CI: 0.61-825.08; P ¼ .06), decreased motility (OR: 5.6; 95% CI: 0.65-39.85; P ¼ .06), and circumferential wall thickening (OR: 4.0; 95% CI: 0.70-41.15; P ¼ .1), all marginally significant. No specific MRE findings correlated with the addition or substitution of medication. The presence of abscess or phlegmon on MRE was greatly associated with referral for surgery or hospitalization (OR: 23.2; 95% CI: 0.94-1390.22; P ¼ .03).
Association Between Clinical Factors and Change in Management
All patients with a CRP level above 9.7 had a change in management. Patients who had a change in management had an average CRP of 6.85 compared to 2.05 for those who did not (P ¼ .01). Patients referred to surgery had a higher CRP than patients not referred to surgery (36.1 vs. 7.67; P ¼ .02).
Age, gender, disease location, disease behavior, and smoking status were not statistically related to change in management. The presence of perianal disease was marginally negatively associated with a change in dose of medication (relative risk: 1.26; 95% CI: 1.09-1.46; P ¼ .05).
Association Between Specific Clinical Variables, MRE Findings, and Change in Management After Correction for Other Variables
CRP values were shown to be significantly associated with change in management. Of the MRE variables, circumferential wall thickening was almost significantly associated with change in management. Circumferential wall thickening, decreased motility, and tethering of adjacent mesentery all had a marginally significant relationship with change in dose of medication. No finding was significantly or marginally significantly associated with change in medication. CRP values showed a significant relationship to hospitalization and surgery, and the relationship between the presence of abscess or phlegmon on MRE and decision to hospitalize or perform surgery was marginally significant (Tables 4 and 5 ). Values are n (%). 
Ordinal Outcome Analysis
Using ordinal outcome analysis, having an abnormal MRE was associated with a worse outcome compared to having a normal MRE (P ¼ .006). MRE findings that correlated with worse outcomes in the ordinal analysis included circumferential wall thickening (P ¼ .02), reactive lymph nodes (P ¼ .04), and presence of abscesses (marginally significant, P ¼ .06).
Discussion
The evaluation of patients with CD has evolved tremendously in recent years with the development of innovative imaging techniques. The use of MRE has emerged as a sensitive and specific method to detect abnormalities associated with active and fibrostenotic disease. Our retrospective study attempted to highlight specific findings on MRE that influenced gastroenterologists in their management of patients with CD.
When compared to previously published epidemiological studies on the disease characteristics of patients with CD, the patients that were referred for disease evaluation by MRE in our study were more likely to have small bowel disease (89%), and more complex disease behavior as shown by the high proportion of patients with stricturing as well as penetrating disease, defined as subacute and chronic perforations resulting in abscess and fistula formation (63.7%). In the Olmsted County study, the incidence of small bowel disease was 70% [17] . Patients with small bowel disease or more complex disease benefit from a noninvasive imaging technique as disease evaluation by the usual colonoscope will likely miss possible signs of active disease in the small bowel.
We believe that in our study, management decisions of gastroenterologists were mainly based on clinical criteria and MRE, and not on other imaging studies.
One abdominopelvic CT 2 months prior to MRE revealed an abscess, which was subsequently drained using ultrasound guidance within a few days. The subsequent MRE for this patient demonstrated active small bowel disease, compatible with recurrence of the disease, and no abscess recurrence. Thus, it is likely that change in management was mostly based on the active small bowel disease seen on MRE, with a possible contribution of the prior abscess formation seen on CT and ultrasound. Our data demonstrates that prior exams were rare and that these studies had very little impact on clinical decision making while waiting for MRE except for one case of abscess drainage.
Only 7 cases (10.6%) were hospitalized or underwent surgical intervention. This is strikingly different from another study that reported a 44% rate of surgical intervention in their patient population [15] . Although both studies included patients with complicated CD, our centre favored medical management for patients with evidence of fistulizing disease and reserved surgical intervention for severely malnourished patients or those that showed signs of an abscess.
Our study demonstrated an elevated CRP at the visit preceding the MRE to be an independent variable in determining management change. For simplicity, we used CRP as the sole clinical marker of inflammation and did not make use of markers such as erythrocyte sedimentation rate, white blood cell count, fecal markers, and albumin, which may have longer half-lives or interference with other factors, which render them less useful in clinical practice [18] .
In addition, our analysis has shown that findings known to be markers of active CD, such as circumferential wall thickening and reactive lymphadenopathy, were associated with a change in management. Therefore, gastroenterologists aim to control not only symptomatic disease or elevated inflammatory biomarkers, but also radiological evidence of active disease. By the same token, it would be expected in patients with such findings on MRE, that the most common change in management should include addition of potent anti-inflammatory medications.
Presence of tethering of adjacent bowel loops, and decreased motility, which are usually associated with obstructive symptoms, such as bloating or crampy abdominal pain, were shown to lead to a change in dose of medication. As these findings were not thought to be related with a proinflammatory state, it seems that gastroenterologists do not feel the need for a more dramatic change of management There is thickening and wall enhancement of the terminal ileum with narrowing of the lumen (thick arrow) compatible with acute on chronic inflammation. This patient had a C-reactive protein of 0.59 and was mildly symptomatic on infliximab for many years. Post MRE the patient was clinically stable. Given the magnetic resonance findings, however, the patient was started on Imuran and higher doses of infliximab. other than optimizing current medication regimen. Similarly, CRP, a marker of inflammation, did not correlate with change in dose of medication. Interestingly, patients with known perianal disease were less likely to have a change in dose of medication. As this group of patients is more likely to suffer from suppurative than nonsuppurative complications, gastroenterologists may feel that the benefit gained from increasing the dose of medication may not be sufficient to provide substantial relief of perianal disease.
Unfortunately, we did not identify specific findings on MRE that were correlated with the addition or substitution of medication. Also, the presence of fistulous tract on MRE did not seem, in our data, to have an impact on management. Both these findings are more likely to stem from our small sample size rather than demonstrate true lack of association.
Our data also shows that the presence of an abscess or phlegmon was strongly associated with referral for surgical intervention and hospitalization. Abscess management depends on a variety of factors such as the patient's clinical presentation, the size of the abscess, its location, and a history of bowel surgery. Although more invasive, the literature seems to suggest improved outcomes after surgical intervention for abscess management. The literature also shows surgical intervention to be associated with therapeutic success and decreased risk of recurrence when compared to medical or percutaneous therapy. Although the latter options are theoretically used to obviate the need for surgical intervention in the acute setting, most of these patients will eventually require surgical intervention due to failure of medical therapy [19, 20] .
As the management of CD is shifting towards achieving a normal appearing mucosa rather than symptomatic treatment alone, it has been proposed that MRE may be used in some instance as an alternative to endoscopy for such evaluations [21] . Patients that may benefit from MRE as a substitute for colonoscopy include those with small bowel disease, multiple previous surgeries, tortuous or otherwise difficult to navigate bowel, and intolerance to endoscopy. The MaRIA has been proposed as a tool to evaluate disease severity based on [11, 13] . In their recent study, Rimola et al attempted to correlate MaRIA with the CDEIS, reference gold standard for endoscopic evidence of disease [22, 23] . They were able to show a good degree of correlation between the CDEIS score and the MaRIA grading system validating it as an appropriate tool for grading severity of disease [12, 13] . It remains to be assessed whether targeting such endpoints as suggested by MaRIA will have the same value as targeting mucosal healing as assessed by endoscopy.
Although very promising, the downfall of MaRIA is that it does not include parameters important in fibrostenotic disease, which are seen on MRE as linear strictures, or prestenotic bowel dilatation. A severity index that includes these findings would provide a more comprehensive assessment of disease activity. Furthermore, MaRIA does not guide the physician in selecting a type of management over another. Our study highlights parameters that are most likely to influence a gastroenterologist's management of Crohn's patients. Being a retrospective study, our findings serve as suggestions for future research, and need to be validated prospectively. Such validated models will aid not only radiologists in deciding which findings of MRE in Crohn's patients are more clinically significant, but also aid gastroenterologists in making more informed decisions in patient management.
The limitations of our study lie in its retrospective design and small power. Although similar studies have used comparable numbers, our sample size was potentially too small for our purpose of detecting all potential significant findings. For instance, indications for surgical intervention in patients with CD likely include more factors than just the CRP level and the presence of an abscess, as suggested by our results.
A simplified approach to patient management based on CRP and MRE results has been proposed in a schematic algorithm, as suggested by our analysis (Figure 1 ). Some notable examples of pathology as shown by MRI have been included (Figures 2 and 3) .
Conclusion
In conclusion, MRE abnormalities lead to a change in patient management in CD by highlighting ongoing disease activity. Specifically, based on our data, circumferential wall thickening, reactive lymph nodes, decreased motility, tethering of bowel loops, and presence of abscess all correlate significantly with change in management. Serological biomarkers of inflammation remain important in influencing change in management.
